Effect of AF, olaparib and aurola treatment on immune-related
$ 27.00 · 4.7 (271) · In stock
Immune gene pathway expression in olaparib-treated PDX models and in
Revealing the selective mechanisms of inhibitors to PARP-1 and PARP-2 via multiple computational methods [PeerJ]
Non‐coding RNA‐associated competitive endogenous RNA regulatory networks: Novel diagnostic and therapeutic opportunities for hepatocellular carcinoma - Khashkhashi Moghadam - 2022 - Journal of Cellular and Molecular Medicine - Wiley Online Library
Christophe DEBEN, PostDoc Position, PhD
Jinthe VAN LOENHOUT, PhD Student
PDF) Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS- Mediated Cell Death in Mutant p53 Cancers
Effect of AF, olaparib and aurola treatment on immune-related
The intracellular gold concentration levels caused by the
Frontiers The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
Current and future strategies for the treatment of ES-SCLC
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
In the Pipeline: Emerging Therapy for Acute Myeloid Leukaemia
Jinthe VAN LOENHOUT, PhD Student
The intracellular gold concentration levels caused by the
Olaparib alone or in combination with anti-PD-L1 alters frequency of